Greenwich LifeSciences (GLSI), a clinical-stage pharmaceutical company, has published upbeat data on Phase IIB clinical trials of it’s lead product “GP2” at the San Antonio Breast Cancer Symposium today. Their 5-year clinical trial showed 100% effectiveness of GP2, an immunotherapy preventing recurrent breast cancer after previous surgery.
The Texas-based micro-cap experienced enormous growth of their share price after presenting these results. Previously valued at around $5, shares skyrocketed to close at $57.10.
This buying spree is fuelled by new hope on extraordinary effectiveness of GP2. While breast cancer has a recurrence rate of 30% average, the Treatment achieved a 0% rate for recurrence of breast carcinomas.